Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 209

Similar articles for PubMed (Select 17172427)

1.

Assessment of celecoxib pharmacodynamics in pancreatic cancer.

Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H, Tanaka K, Danenberg K, Messersmith WA, Almuete V, Hruban RH, Maitra A, Yeo CJ, Hidalgo M.

Mol Cancer Ther. 2006 Dec;5(12):3240-7.

2.

Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.

Raut CP, Nawrocki S, Lashinger LM, Davis DW, Khanbolooki S, Xiong H, Ellis LM, McConkey DJ.

Cancer Biol Ther. 2004 Dec;3(12):1217-24. Epub 2004 Dec 9.

PMID:
15477758
3.
4.
5.

Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo.

Xu XF, Xie CG, Wang XP, Liu J, Yu YC, Hu HL, Guo CY.

Tohoku J Exp Med. 2008 Jun;215(2):149-57.

6.

Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.

Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, Mukhtar H.

Cancer Res. 2004 May 1;64(9):3334-43.

7.

Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor.

Eibl G, Takata Y, Boros LG, Liu J, Okada Y, Reber HA, Hines OJ.

Cancer Res. 2005 Feb 1;65(3):982-90.

8.

Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.

Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ.

Clin Cancer Res. 2005 Mar 1;11(5):1999-2007.

10.

Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.

Ohtsu N, Takaoka K, Segawa E, Hashitani S, Noguchi K, Kishimoto H, Urade M.

Oncol Rep. 2010 Jul;24(1):31-6.

PMID:
20514441
11.

Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer.

Zhou Y, Ran J, Tang C, Wu J, Honghua L, Xingwen L, Ning C, Qiao L.

Cancer Biol Ther. 2007 Feb;6(2):269-75. Epub 2007 Feb 26.

PMID:
17224647
12.
13.

Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.

Ninomiya I, Nagai N, Oyama K, Hayashi H, Tajima H, Kitagawa H, Fushida S, Fujimura T, Ohta T.

Oncol Rep. 2012 Sep;28(3):777-84. doi: 10.3892/or.2012.1885. Epub 2012 Jun 26.

14.

Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice.

Quidville V, Segond N, Tebbi A, Cohen R, Jullienne A, Lepoivre M, Lausson S.

Thyroid. 2009 Jun;19(6):613-21. doi: 10.1089/thy.2008.0194.

PMID:
19281427
15.

Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.

Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL.

Cancer Res. 2002 Feb 1;62(3):625-31.

16.

Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.

Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P.

Mol Cancer Res. 2004 Nov;2(11):632-42.

17.

Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.

Ferrandina G, Ranelletti FO, Legge F, Lauriola L, Salutari V, Gessi M, Testa AC, Werner U, Navarra P, Tringali G, Battaglia A, Scambia G.

Clin Cancer Res. 2003 Oct 1;9(12):4324-31.

18.

Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models.

Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN.

Cancer Res. 2000 Nov 1;60(21):6045-51.

19.

Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.

Lev-Ari S, Zinger H, Kazanov D, Yona D, Ben-Yosef R, Starr A, Figer A, Arber N.

Biomed Pharmacother. 2005 Oct;59 Suppl 2:S276-80.

PMID:
16507392
20.

Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells.

Cianchi F, Cortesini C, Magnelli L, Fanti E, Papucci L, Schiavone N, Messerini L, Vannacci A, Capaccioli S, Perna F, Lulli M, Fabbroni V, Perigli G, Bechi P, Masini E.

Mol Cancer Ther. 2006 Nov;5(11):2716-26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk